+44 (0)1223 298875

Anti-Phospho-ErbB 2 Antibody (FITC)

 
Rabbit polyclonal antibody to Phospho-ErbB 2 (FITC) from FabGennix (PHER2-FITC).
Overview
Name: Anti-Phospho-ErbB 2 Antibody (FITC)
Description: Rabbit polyclonal antibody to Phospho-ErbB 2 (FITC)
Applications: ELISA, IP, WB
Dilutions: DB: 1:10,000; ELISA: 1:10,000; Immunoprecipitation: 1:200; Western Blot: 1:500
Reactivity: Mouse, Rat, Predicted: Human
Immunogen: Phoshporylated synthetic peptide taken within amino acid region 1100-1150 on human HER-2 protein
Host: Rabbit
Clonality: Polyclonal
Conjugate: FITC
Concentration: 0 .50 µg/µl in antibody stabilization buffer
Storage: -20⁰C for long term storage

Target
Function: Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
Tissue Specificity: Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.
Involvement in Disease: Hereditary diffuse gastric cancer: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body.

Glioma: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
Sequence Similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Post-Translational Modification: Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172).
Cellular Location: Cell membrane. Cytoplasm > Perinuclear region. Nucleus.

Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1.
UniProt: P04626

Please Note: Anti-Phospho-ErbB 2 Antibody (FITC) is for research use only. It is not intended for diagnostic of therapeutic use.
Antibodies.com | PHER2-FITC
Size Price Quantity
100µg £475

or
Request a quotation
Contact Us Directly
  • call icon +44 (0)1223 298875
  • +44 (0)1223 281447
  • email icon orders@antibodies.com
Product Quality
  • guarantee icon
  • We promise guaranteed product quality
  • and expert customer service.
Lead Time: Currently 5-6 Days
Shipping Information
  • £20 to United Kingdom
  • £35 to Europe